Dolutegravir Sodium Patent Expiration
Dolutegravir Sodium was first introduced by Viiv Healthcare Co
Dolutegravir Sodium Patents
Given below is the list of patents protecting Dolutegravir Sodium, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Tivicay | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
Tivicay |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
Tivicay | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
Tivicay |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
Tivicay Pd | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
Tivicay Pd |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
Tivicay Pd | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
Tivicay Pd |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳